Revolution Medicines Inc (RVMD) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Revolution Medicines Inc   (NASDAQ: RVMD)


Revolution Medicines Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Revolution Medicines Inc's ROI in the second quarter of 2026?
Revolution Medicines Inc had a negative return on investment (ROI) of -74.87%, due to the net loss of $-1 billion, during the twelve months ending in the second quarter of 2026.

Within the Healthcare sector 558 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2224 to 3848.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 11.25 % -1.3 % 10.88 % 23.6 % 35.35 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 3,613 1,893 2,021 1,921 2,128
Return On Investment (TTM) -74.87 % -68.91 % -53.95 % -43.88 % -38.25 %
RVMD's Overall Ranking # 3848 # 2224 # 3389 # 3139 # 3220
Seq. Investment Change TTM 18.65 % -5.07 % -4.26 % 3.16 % 5.26 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -1,768 -1,372 -1,131 -961 -812

RVMD Company Profile >> Back to RVMD Roi Comparisons >> See Annual RVMD Return On Investment



Return On Investment RVMD's Ranking
Within: No.
Industry # 89
Sector # 559
Overall # 3848

Return On Investment Statistics
High Average Low
-21.06 %
-34.37 %
-70.73 %
(Mar 31 2020)   (Jun 30 2026)



  News about Revolution Medicines Inc Return on Investment ROI

Promising Advances in Targeted Therapy for Metastatic Pancreatic Ductal Adenocarcinoma Insights from the RASolute 303...

September 10, 2025

Metastatic pancreatic ductal adenocarcinoma (mPDAC) remains one of the most challenging malignancies to treat, often associated with poor prognosis and limited therapeutic options. Revolution Medicines Inc. has recently announced new clinical results supporting the initiation of RASolute 303, a global Phase 3 registrational trial of daraxonrasib in patients with first-line mPDAC. This article reviews the clinical activity and durability of daraxonrasib based on long-term follow-up data from its use as monotherapy in second-line treatment settings, highlighting the implications for treatment protocols in this aggressive cancer type, while also addressing the concurrent financial performance trends at Revolution Medicines.Pancreatic ductal adenocarcinoma (PDAC) is renowned for its aggressive behavior and resistance to standard therapies. The RAS oncogene, frequent in PDAC, presents a pivotal target for developing innovative treatments. Daraxonrasib a targeted therapy designed to inhibit RAS signaling pathways has shown promising results in early clinical trials. With the launch of the global Phase 3 RASolute 303 trial, Revolution Medicines aims to evaluate the potential of daraxonrasib as a first-line treatment for patients with mPDAC.





Financial Statements
Revolution Medicines Inc's II. Quarter Investments $ 3,613 Millions RVMD's Balance sheet
Revolution Medicines Inc's II. Quarter Income $ -644 Millions Quarterly RVMD's Income Statement
RVMD's Income by Division See RVMD's Income by Division


RVMD Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2,021 2,394 1,918 685 678
Y / Y Investment Growth -15.58 % 24.85 % 179.78 % 1.16 % 42.57 %
Net Income in Millions -1,131 -600 -436 -249 -187
Y / Y Net Income Growth - - - - -
Annual Return On Investment -55.96 % -25.06 % -22.75 % -36.28 % -27.61 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RVMD's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RVMD's Competitors
Subscribers only: Roi for Revolution Medicines Inc's Suppliers
Subscribers only: Return On Investment for RVMD's Customers

Other Ratios
RVMD's Roa RVMD's Inventory Turnover Ratio RVMD's Growth Rates RVMD's Dividend Statistics
RVMD's Profitability Ratios RVMD's Asset Turnover Ratio RVMD's Dividend Growth
RVMD's Roe RVMD's Valuation Ratios RVMD's Financial Strength Ratios RVMD's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-10T17:22:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.